Amyl Therapeutics
Amyl Therapeutics is a preclinical stage biotechnology company developing a technology platform to treat diseases linked to amyloid fibrils. From its funding announcement.
In their own words
What Amyl Therapeutics says it is doing
Public signal Described in the funding announcement as "preclinical stage biotechnology company developing a technology platform to treat diseases linked to amyloid fibrils". Source
Public signal Read from the company's own description of what the funding supports.
Why now
Where Amyl Therapeutics is today
Amyl Therapeutics announced a Series A round of €8M on 1 September 2026.
Momentum AfterRaise intelligence
AfterRaise Score
- Hiring momentum Open roles and hiring pace
- Market expansion New offices and new countries
- Leadership Executive appointments
- Product activity Launches and releases
Since the raise
What has happened since
- 1 September 2026€8M Series AInvestors not stated in the announcement.
Public signal The timeline currently holds funding events, because those are the signals AfterRaise observes today. Hiring, leadership, expansion and product events join it with the signals layer.
What may happen next
What this raise could create
What may happen next
- Product launches and new tiers
- Product leadership hiring
- Research programme expansion
- Scientific team growth
Opportunities this could create
- Clinical operations
- CMC and manufacturing
- Quality systems
- Scientific hiring
- Licensing and BD partnerships
Based on the Biotech & Pharma sector, a Series A round and the priorities the company itself set out. Not a statement of fact.
- 1 September 2026€8M Series A announced
- 1 September 2026Stated priority: product
- 1 September 2026Stated priority: research and development
- 1 September 2026Stated priority: manufacturing and scale
High momentum means several meaningful company changes have occurred in a short period. Signals here are funding events and the priorities the company stated; hiring, leadership and expansion detection join with the signals layer.
Open to
What Amyl Therapeutics is open to
Not yet specified
Amyl Therapeutics has not told AfterRaise which approaches it welcomes. Until it does, we do not assume. Offers to help are held and shown to the company, and the company decides whether to open a conversation.
Work here? Set your preferencesOpportunities
Ways to work with Amyl Therapeutics
No open opportunities listed
Jobs, projects, partnerships, advisory and supplier needs appear here once the company has claimed its page and published them, and any role we read from its own job board appears automatically.
Work here? Open the first oneHelpful contributors
People who have contributed here
Nobody yet
When someone offers help and the company says it was useful, they appear here. Reputation on AfterRaise is built from contributions the company confirmed, not from follower counts.
Do you work at Amyl Therapeutics?
Claim your company profile.
This page was created from publicly available information. A verified representative corrects the record, says what the company is building next and chooses which conversations it welcomes.
What we do not have yet: your website and the roles and projects you have open. Claiming the page is how you fill those in.
Someone else requesting access does not give them ownership. Every representative is verified by a person before access is granted.
Maintaining your own company profile is free. A founder, CEO or authorised senior colleague can represent the company.
Also moving